Kornimate/medical-research-clean huggingface dataset:
a randomized trial comparing 2 methods for rapid induction of cooling in stroke patients, cold infusions vs. emcools brain.pad (icool 3)

Conditions: Ischemic Stroke; Hemorrhagic Stroke

Summary: mild hypothermia improves outcome in patients with global cerebral ischemia after cardiac arrest. hypothermia seems promising also in other acute hypoxic-ischemic or in brain swelling associated cerebrovascular disease. the narrow-time-frame is a major issue ("time is brain"). to provide immediate cooling without delay, easy to use, mobile and effective methods are needed. cold infusions (4 °c) are an accepted standard worldwide. emcools brain.pad (emergency medical cooling systems ag, wien, austria) is a new non-invasive surface cooling system. a comparison of these two induction methods has never been done before. neither was the effect of the emcools brain.pad on brain-temperature measured. for the first time icool 3 compares feasibility, safety and efficacy of the two methods.


Eligibility criteria:
inclusion criteria: * sedation * combined icp-temperature-probe * indication to lower body temperature ≤ 1.5°c * age ≥ 18 years exclusion criteria: * body weight \> 120 kg * severe renal insufficiency * acute pulmonary embolism * acute myocardial infarction * high-grade heart valve stenosis or insufficiency * severe cardiac insufficiency (nyha ≥ iii) * threatening ventricular dysrhythmia * cardiac dysrhythmia with bradycardia (heart rate \ 450 ms, sick sinus syndrome, av-block ii-iii°). * known hematologic disease with increased risk of thrombosis (e.g. cryoglobulinemia, cold agglutinins, sickle cell anemia) * known vasospastic vascular disorder (e.g. raynaud's phenomenon or thromboangiitis obliterans) * skin lesions not allowing a secure application of the emcools brain.pad

Keywords: hypothermia induction of hypothermia cold infusion local neck cooling external cooling surface cooling non invasive cooling stroke intracranial hemorrhage cerebrovascular disease neuro intensive care
adjunct bicarbonate in local anaesthesia for carpal tunnel release (delicate)

Conditions: Carpal Tunnel Syndrome

Summary: introduction carpal tunnel syndrome (cts) is the most common peripheral nerve entrapment syndrome in finland and worldwide. nowadays carpal tunnel release (ctr) surgery is often done in local anaesthesia. often the most painful event during ctr is the injection of the local anaesthetic. multiple different methods have been trialed and buffering the local anaesthetic seems to have good results in reducing the pain caused by the injection. however, no study has buffered long-acting local anaesthetic in ctr surgery, and no study has accounted for the patient's individual pain tolerance in the groups. there are no comparisons of the results to minimal clinically important difference (mcid) for pain. hypothesis in this study the investigators will evaluate the effects of buffering long-lasting local anaesthetic in wide-awake local anaesthesia no tourniquet (walant) ctr. this study's hypothesis is that buffering long-acting local anaesthetic with sodium bicarbonate decreases the pain of the injection. the investigators also expect that buffering will reduce the number of needle stings felt during injection, will result in as good perioperative pain control, will lengthen the effect of anaesthetic, will reduce postoperative painkiller usage, will have at least as good functional outcome and greater patient satisfaction. methods this study will enlist 116 patients and divide the patients into two groups in this double blinded randomized controlled trial. one group receives non-buffered, and the second group buffered local anaesthetic. this study's primary outcome is to compare burning, pressure, needle sting and total pain the patient experienced between the groups. the investigators will assess this using vas, and will compare the results to mcid. the investigators secondary outcomes are comparisons of expected injection pain level and pain during ctr with vas, individual pain tolerance/catastrophising tendency with preoperative pcs-finv2.0 form, the number of needle stings the patient feels during the injection, functional outcome and improvement of the patients' symptoms with the boston carpal tunnel questionnaire (likert 5) before and after the surgery, evaluation of patient satisfaction with net promoter score (nps) and the use of painkillers, duration of analgesia and pain levels using vas after the surgery until the 3rd postoperative night.


Eligibility criteria:
inclusion criteria: * clinically and electrophysiologically diagnosed carpal tunnel syndrome * patients who are scheduled for carpal tunnel release surgery. exclusion criteria: * associated disease or conditions, including earlier injury to median nerve, cervical radiculopathy, cubital tunnel syndrome and other peripheral neuropathy * chronic renal failure * rheumatoid arthritis * allergies to lidocaine * pregnancy * profound cognitive impairment * previous ipsilateral carpal tunnel decompression

Keywords: carpal tunnel release bicarbonate local anaesthesia wide awake lidocain cum adrenalin no tourniquet pain carpal tunnel syndrome
advance care planning in the emergency department

Conditions: Congestive Heart Failure; Metastatic Cancer; Chronic Kidney Disease Requiring Chronic Dialysis; Chronic Obstructive Pulmonary Disease

Summary: this is a two-armed, parallel-design, pre-/post-intervention assessment study. the investigators will conduct a randomized controlled trial for ed goal on a cohort of 120 older adults with serious illness to collect patient-centered outcomes and determine preliminary efficacy on increasing advance care planning engagement (self-reported and/or in the electronic medical record) one month after leaving the emergency department. the investigators will also conduct qualitative interviews with participants of ed goal.

ed goal, a 6-minute motivational interview conducted in the emergency department (ed), which engages participants to address advance care planning (acp) conversations with their outpatient clinicians and avoids a time-consuming, sensitive conversation in the time-pressured ed environment. this study is designed to determine the preliminary efficacy of ed goal on increasing acp engagement (by self-report and in the electronic medical record) one month after leaving the ed.

Eligibility criteria:
inclusion criteria: 1. ≥50 years of age and ≥1 serious illness\* or ed clinician would not be surprised if patient died in the next 12 months (a validated prognostic sign) 2. english-speaking 3. capacity to consent 1. patient with mild cognitive impairment or mild dementia with capacity to consent (requires a caregiver/study partner to enroll) 2. caregiver of patient with moderate/severe dementia with capacity to consent (\*) nyha stage iii/iv congestive heart failure, chronic obstructive lung disease on home oxygen, chronic kidney disease on dialysis, or metastatic solid tumor cancer. in addition, patients with nyha stage i/ii congestive heart failure, chronic obstructive lung disease not on home oxygen, chronic kidney disease not on dialysis will be included if recent hospitalization in the last 12 months exists. exclusion criteria: 1. acute physical or emotional distress 2. determined by treating or study clinician not to be appropriate 3. clearly documented goals for medical care\*\* (unless the treating or study clinician recommends that the intervention is clinically indicated) 4. delirium (assessed using 3d-cam) 5. already enrolled in this study 6. unable/unwilling to schedule the follow-ups on the calendar 7. receive both the outpatient care for serious illness and primary care outside of the mass general brigham health system (\*\*)e.g., molst, medical order for life-sustaining treatment, documented serious illness conversations in clinician notes within the last 3 months, etc.

Keywords: advance care planning palliative care goals of care ed goal
choroidal response to novel spectacle lens to control myopia progression

Conditions: Myopia, Progressive

Summary: diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.

diurnal variations in the thickness of the choroid have been reported in the literature , and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression. sightglass vision, inc is conducting a multi-site, randomized, controlled, interventional study to confirm the efficacy and safety of spectacle lenses designed to inhibit the progression of myopia by reducing image contrast in peripheral vision. core is participating as a clinical site in this three year study which aims to compare changes in ocular length and cycloplegic auto-refraction in children randomised to wear one of either two test or one control spectacle lens designs; the cpro-1802-001 (cypress_sg) study. the sponsor is interested in conducting choroidal thickness measurements only at core's site by inviting those participants who have already been found eligible for the cpro-1802-001 study to participate in this parallel study.

Eligibility criteria:
inclusion criteria: * participating in the cpro-1802-001 (cypress_sg) study at core * read and signed an assent and their parent/guardian has signed an information consent letter exclusion criteria: * transient health condition which may affect the eye(s) (e.g. a common cold, active allergies, fatigue, etc;)

Keywords: myopia myopia control
wearable auscultation device validation in children

Conditions: Asthma; Asthma in Children; Wheezing; Pediatric Asthma

Summary: this observational clinical study is an evaluation of a diagnostic tool through comparison. similar to a validation study, the output of the resp device will be compared to physician auscultation, surrogated by having an attending pulmonologist listen to blinded recordings.


Eligibility criteria:
inclusion criteria: * any child aged 4-17 years of age * admitted to lurie children's hospital or the emergency department at lurie * normal breath sounds cohort: (16 patients ages 4-10, 16 patients ages 11-17) * admitted for a non-respiratory complaint * normal breath sounds on screening examination * wheeze cohort: (53 patients ages 4-10, 53 patients ages 11-17) * admitted for pathologic process that may lead to wheezing (e.g., asthma) * presence of wheeze on screening examination exclusion criteria: * children less than age 4, adults (age 18 and above) * patients in the ambulatory setting * unable to provide consent * intubated patients * unstable disease posing a threat to life * adhesive allergy
m-gard particulate ew efficacy study on seasonal allergic rhinitis

Conditions: Allergic Rhinitis Due to Grass Pollens

Summary: the goal of this clinical trial is to assess the efficacy and safety of m-gard supplementation for alleviating the symptoms of allergic rhinitis.


Eligibility criteria:
inclusion criteria: * adults aged 18-65 years. * generally healthy * individuals with a history of recurrent seasonal allergic rhinitis * positive rast test for grass allergy * bmi 18-35kg/m2 * able to provide informed consent * agree not to change current diet and/or exercise routine during entire enrolment period * agree to not participate in another clinical trial during the study period exclusion criteria: * serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, neurological disorders such as multiple sclerosis. * unstable illness e.g., diabetes and thyroid gland dysfunction. * current malignancy (excluding basal cell carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years. * individuals with symptomatic perennial allergic rhinitis, non-allergic rhinitis, chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease). * participants with cognitive damage. * acute illness experienced in the past 1 month. * active smokers and/or nicotine or drug abuse. * allergic to any of the ingredients in the active or placebo formula. * chronic past and/or current alcohol use (\>21 alcoholic drinks per week) * attempting to conceive, pregnant or lactating women * use of medications that would affect the immune and/or the inflammatory response e.g. immunotherapy, antihistamines (daily use), corticosteroids, mast cell stabilizers, leukotriene modifiers, and decongestants. * currently taking coumadin (warfarin), heparin, dalteparin, enoxaparin or other anticoagulation therapy including low dose aspirin; tricyclic antidepressants; clonidine and other central acting alpha-2-agonists. * participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month. * any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.

Keywords: allergic rhinitis
ablation efficacy of contact side firing fiber in predefined settings for treating bph

Conditions: Treatment of Benign Prostatic Hyperplasia

Summary: twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device.follow up visits are scheduled for the day of release from the hospital and at 1 and 3 months post procedure. the primary objective of this study is to explore vaporization efficacy and safety when treating pbh (benign prostatic hyperplasia ) with the contact side firing fiber with recommended settings.


Eligibility criteria:
inclusion criteria: * subject will be older than 18 years of age * subject was diagnosed with enlarged prostate of ≥ 30 gr volume * subject is a candidate for surgery treatment * subject is willing and has signed the informed consent form * aua score ≥ 12 * qmax \<15 ml/s exclusion criteria: * need to perform concomitant procedure, other than prostate vaporization * pvr \> 300ml * current urine retention and pdet \<40 cm h20 * documented or suspected prostate cancer and / or bladder cancer * neurogenic bladder disorder / neurogenic voiding dysfunction * urethral strictures * previous prostatic, bladder neck, or urethral surgery * known history of spinal cord injury * urogenital trauma * bladder neck stricture * evidence of urinary tract infection * history of chronic prostatitis
effects of a biopsychosocial-spiritual group intervention on quality of life of institutionalized seniors

Conditions: Quality of Life

Summary: this study aimed to evaluate the effects of a biopsychosocial-spiritual (bps-s) group intervention on quality of life among seniors with disabilities in long-term care residential settings.

background: traditionally, biomedical care approach has been insufficient to meet the complex needs of older people living with multi-morbidity. promoting whole-person wellness and better quality of life becomes a key goal of care in residential long-term care facilities. the integrative approaches composed of physio-psycho-social and spiritual components might be a viable strategy to assist older adults accept uncontrollable life changes and enhance holistic wellness. purpose: the study purpose was to develop and evaluate the effects of 8-week biopsychosocial-spiritual (bps-s) group intervention versus usual care on self-perception of quality of life (qol) and meaning in life among seniors with disability in residential care home at mid- and post-intervention, and at a 1-month follow up. methods: this single-blind randomized controlled trail with repeated measures design was conducted in residential long-term care facilities. both the experimental groups (eg) and the control group (cg) received routing group activities based on their institution's schedule. additionally, the eg received 8 sessions of weekly bps-s group therapy for 80 minutes each. the baseline characteristics of residents with disabilities (including demographic information, length of stay in the institution and medical conditions) were collected using a data sheet, and activities of daily living of these residents were measured using the barthel index. to evaluate the effectiveness of the bps-s group therapy, the primary outcomes including "participants' overall qol" and the secondary outcome "meaning in life" were assessed at four time points: before, mid- and post- intervention and at a 1-month follow up. quality of life index (qli)-part i and purpose in life (pil) test were used to measure these outcome variables, respectively.

Eligibility criteria:
inclusion criteria: 1. being 65 years of age or older; 2. living in the institution for at least 1 month; 3. barthel index scores under 90; 4. no hearing, visual impairment and infectious diseases; 5. being able to follow instructions and participate in group activities. exclusion criteria: have the diagnosis of major depression.

Keywords: quality of life institutionalized seniors disabilities meaning in life biopsychosocial-spiritual group intervention
human menopausal gonadotropin combining with human chorionic gonadotropin treat congenital hypogonadotropic hypogonadism

Conditions: Kallmann Syndrome; Hypogonadotropic Hypogonadism

Summary: observe the therapeutic efficacy of human menopausal gonadotropin combining with human chorionic gonadotropin in adolescent boys with congenital hypogonadotropic hypogonadism.

observe safety and efficacy of human menopausal gonadotropin and human chorionic gonadotropin treating congenital hypogonadotropic hypogonadism in teenagers; which as clinic recommendation, may provide clinical basis for establishing standard treatment guideline in the future. establish technological process and follow-up precept for human menopausal gonadotropin and human chorionic gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers. and find safety and effective dose for teenagers.

Eligibility criteria:
inclusion criteria criteria a * boy \>14yr without any sign of puberty, testis \<4ml * ba ≥12yr * sex hormone (lh,fsh, t) are pre-pubertal level * no other hormones problems (other pituitary glands axis are normal except gonad axis) * no space occupying lesion, no tumor on mri of pituitary and hypothalamus area * kallmann's syndrome(ks) patients may companies with dysosmia or dysplasia of olfactory bulb or olfactory tract on mri * karyotype is 46，xy * exclude chronic diseases, malnutrition criteria b * for the boy \<14yr. who companies with micropenis or cryptorchid or hypospadias and they have anosmia or dysplasia of olfactory bulb/olfactory sulcus/olfactory structs on mri include in. criteria c * as the phenotype of hypogonadotropic hypogonadism are variant, some of them may have partial puberty. so, we enrolled them when they have testis volume \>4ml or the testosterone level \>200ng/l，companies anosmia or dysplasia of olfactory bulb /olfactory sulcus/ olfactory structs on mri, and the puberty arrested in half a year. these patients can be diagnosed as kallmann syndrome. exclusion criteria: * any ascertain reason contributes to the non puberty development (chromosome abnormal, trauma, surgeries) or any ascertain disease such as prader-willi syndrome or hypergonadotropic hypogonadism * systemic diseases (such as chronic kidney failure, mediterranean anemia, poor controlled diabetes) * protein-energy malnutrition * eating disorder (such as anorexia nervosa, binge eating) * any brain diseases history: tumors in brain or pituitary or after their surgeries
analysis of cell-free dna (cfdna) during periodontitis

Conditions: Periodontal Diseases; Cardiovascular Diseases

Summary: the purpose of this study was to examine the association between circulating cfdna concentration and cvd risk in patients with periodontitis, cvd, and periodontitis plus cvd. in addition, the secondary objective was to identify, among other confounders, the impact of periodontitis and cardiovascular disease as potential significant predictors of circulating cfdna levels in the enrolled population.

recent emerging evidence has shown that circulating cell-free (cf) dna are involved in in several epigenetic processes linked with periodontitis, coronary stenosis and systemic inflammation. the present study was aimed at assessing the impact of periodontitis on circulating cfdna levels and evaluating possible confounders that influenced this association. healthy controls (n=30) and subjects with cvd (n=31), periodontitis (n=31) and periodontitis+cvd (n=30) were enrolled. all subjects underwent regular periodontal examination and blood sampling. the analysis of the plasma cfdna concentrations was performed using a dsdna assay kit.

Eligibility criteria:
inclusion criteria: * presence of at least 15 teeth * cp with a minimum of 40% of sites with a clinical attachment level (cal) ≥2mm and probing depth (pd) ≥4mm; * presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs * presence of ≥40% sites with bleeding on probing (bop) exclusion criteria: * intake of contraceptives * intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study * status of pregnancy or lactation * previous history of excessive drinking * allergy to local anaesthetic * intake of drugs that may potentially determine gingival hyperplasia such as hydantoin, nifedipine, cyclosporin a or similar drugs.
healing lodge first face training evaluation study

Conditions: Addiction; Depression/Anxiety; Trauma, Psychological; Self-harm

Summary: the purpose of this study is to evaluate a culturally grounded training program, xaʔtus (meaning first face) for mental health. this program will train community members in how to recognize and respond to youth and adults experiencing mental health crises and ways to serve as a bridge between these individuals and the help they need. all healing lodge staff are being asked to complete first face training. to evaluate first face, the investigators will ask all trainees to complete surveys before and after training, and again 3 months later. these surveys will measure knowledge about mental health and addiction, as well as the ability and confidence to respond appropriately to mental health crises. the study will help the investigators understand whether the first face training program influences mental health and attitudes, as well as responses to mental health crisis situations.

with funding from the national institutes for health, the investigators created first face for mental health. first face is a culturally-appropriate community-based mental health training that prepares trainees to provide assistance to someone having a mental health crisis. the more community members within tribal nations who are trained in a culturally sensitive program to provide support to youth in recovery and members struggling with mental health problems or crises, the better positioned that community is to create a supportive recovery environment for its youth. the investigators are in the process of launching first face trainings and evaluations among several tribal communities. additionally, they will be training staff from the healing lodge of the seven nations (hl) in the first face program. this particular application concerns the evaluation of first face training among hl staff. the investigators will measure primary and secondary outcomes at pre-training, post-training, and 3-month follow-up.

Eligibility criteria:
inclusion criteria: * employment at the healing lodge of the seven nations * selection to participate in first face for mental health training exclusion criteria: ° previous completion of first face for mental health training

Keywords: mental health prevention addiction substance use disorders